Home
Thursday, 12 June 2025 08:00 – 09:30 CEST Allianz MiCo – Milano Convention Centre | 20149 Milan, Italy Room: Brown Hall 3 CPD Hybrid Multiple myeloma (MM) remains a challenging hematologic malignancy, with most patients experiencing relapse despite initial treatment success. The management of relapsed/refractory MM (R/R MM) has evolved significantly with the advent of novel therapies, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and chimeric antigen receptor (CAR)
